Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 145-154

  Yoo, Dong Jun ^a   Kim, Kang Mo ^a   Jin, Young Joo ^a   Shim, Ju Hyun ^a   Ko, Gi Young ^a   Yoon, Hyun Ki ^a   Sung, Kyu Bo ^a   Lee, Jae Lyun ^a   Kang, Yoon Koo ^a   Lim, Young Suk ^a   Lee, Han Chu ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Metastasis; Sorafenib; Survival analysis; Transarterial chemoembolization

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GELFOAM; GEMCITABINE; OXALIPLATIN; SORAFENIB;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; FEMALE; HUMAN; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LIVER FUNCTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; PLEURA METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SPLEEN CANCER; SPLEEN METASTASIS; SURVIVAL TIME; THERAPY EFFECT; TRANSARTERIAL CHEMOINFUSION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 78650352738     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06341.x     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001; 94: 153-6.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999; 340: 745-50.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
4. Bruix J, Sherman M. Practice Guidelines Committee American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
5. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.
6. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 2004; 15: 439-52.
7. Natsuizaka M, Omura T, Akaike T et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J. Gastroenterol. Hepatol. 2005; 20: 1781-7.
8. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
9. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
10. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007; 72 (Suppl. 1): 30-44.
11. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006; 24: 1898-903.
12. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-38.
13. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
14. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
15. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.
16. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. 2005; 40: 225-35.
17. Okusaka T, Okada S, Ishii H et al. Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 1997; 44: 251-7.
18. Uka K, Aikata H, Takaki S et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J. Gastroenterol. 2007; 13: 414-20.
19. Kim KM, Kim JH, Park IS et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J. Gastroenterol. Hepatol. 2009; 24: 806-14.
20. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
21. Kasugai H, Kojima J, Tatsuta M et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989; 97: 965-71.
22. Lam CM, Lo CM, Yuen WK, Liu CL, Fan ST. Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma. Br. J. Surg. 1998; 85: 1198-200.
23. Nakayama H, Takayama T, Makuuchi M et al. Resection of peritoneal metastases from hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 1049-52.
24. Kurachi K, Suzuki S, Yokoi Y et al. A 5-year survivor after resection of peritoneal metastases from pedunculated type hepatocellular carcinoma. J. Gastroenterol. 2002; 37: 571-4.
25. Anon. Liver including intrahepatic bile ducts. In: Greene FL, Page DL, Fleming ID et al., eds. American Joint Committee on Cancer Staging Manual, 6th edn. New York, NY: Springer, 2002; 131-44.
26. Katyal S, Oliver JH III, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000; 216: 698-703.
27. Shuto T, Hirohashi K, Kubo S et al. Treatment of adrenal metastases after hepatic resection of a hepatocellular carcinoma. Dig. Surg. 2001; 18: 294-7.
28. Si MS, Amersi F, Golish SR et al. Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival. Am. Surg. 2003; 69: 879-85.